SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity[1].
in vivo
SLC7A11-IN-1 (2 mg/kg; i.v.; every three days for consecutive 3 times) inhibits the growth of tumors in mice[1].
Animal Model:
male BALB/c mice (CT26 tumor models)[1]
Dosage:
2 mg/kg
Administration:
I.v.; once every three days, for consecutive 3 times
Result:
Suppressed the growth of tumor by 60.7%.
References
[1] Li Z, et al. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment. Eur J Med Chem. 2023 Mar 15;250:115233. DOI:10.1016/j.ejmech.2023.115233
